134 related articles for article (PubMed ID: 31713727)
1. VGF peptides as novel biomarkers in Parkinson's disease.
Cocco C; Corda G; Lisci C; Noli B; Carta M; Brancia C; Manca E; Masala C; Marrosu F; Solla P; Manconi B; Bongioanni P; Ferri GL
Cell Tissue Res; 2020 Jan; 379(1):93-107. PubMed ID: 31713727
[TBL] [Abstract][Full Text] [Related]
2. VGF modifications related to nigrostriatal dopaminergic neurodegeneration induced by the pesticide fipronil in adult male rats.
Manca E; Noli B; Corda G; El-Hassani M; Manai A; Sanna F; Argiolas A; Melis MR; Manconi B; Contini C; Cocco C
Ann Anat; 2024 Feb; 252():152194. PubMed ID: 38056781
[TBL] [Abstract][Full Text] [Related]
3. Distribution of VGF peptides in the human cortex and their selective changes in Parkinson's and Alzheimer's diseases.
Cocco C; D'Amato F; Noli B; Ledda A; Brancia C; Bongioanni P; Ferri GL
J Anat; 2010 Dec; 217(6):683-93. PubMed ID: 21039478
[TBL] [Abstract][Full Text] [Related]
4. Correlation of dopaminergic terminal dysfunction and microstructural abnormalities of the basal ganglia and the olfactory tract in Parkinson's disease.
Scherfler C; Esterhammer R; Nocker M; Mahlknecht P; Stockner H; Warwitz B; Spielberger S; Pinter B; Donnemiller E; Decristoforo C; Virgolini I; Schocke M; Poewe W; Seppi K
Brain; 2013 Oct; 136(Pt 10):3028-37. PubMed ID: 24014521
[TBL] [Abstract][Full Text] [Related]
5. CART modulates the effects of levodopa in rat model of Parkinson's disease.
Upadhya MA; Shelkar GP; Subhedar NK; Kokare DM
Behav Brain Res; 2016 Mar; 301():262-72. PubMed ID: 26771081
[TBL] [Abstract][Full Text] [Related]
6. VGF Peptide Profiles in Type 2 Diabetic Patients' Plasma and in Obese Mice.
D'Amato F; Noli B; Angioni L; Cossu E; Incani M; Messana I; Manconi B; Solinas P; Isola R; Mariotti S; Ferri GL; Cocco C
PLoS One; 2015; 10(11):e0142333. PubMed ID: 26562304
[TBL] [Abstract][Full Text] [Related]
7. Serotonergic markers in Parkinson's disease and levodopa-induced dyskinesias.
Cheshire P; Ayton S; Bertram KL; Ling H; Li A; McLean C; Halliday GM; O'Sullivan SS; Revesz T; Finkelstein DI; Storey E; Williams DR
Mov Disord; 2015 May; 30(6):796-804. PubMed ID: 25649148
[TBL] [Abstract][Full Text] [Related]
8. Neuroprotection by valproic acid in an intrastriatal rotenone model of Parkinson's disease.
Carriere CH; Kang NH; Niles LP
Neuroscience; 2014 May; 267():114-21. PubMed ID: 24613722
[TBL] [Abstract][Full Text] [Related]
9. Levodopa induction of Fos immunoreactivity in rat brain following partial and complete lesions of the substantia nigra.
Cole DG; Growdon JH; DiFiglia M
Exp Neurol; 1993 Apr; 120(2):223-32. PubMed ID: 8491280
[TBL] [Abstract][Full Text] [Related]
10. Dopaminergic neuroprotection and regeneration by neurturin assessed by using behavioral, biochemical and histochemical measurements in a model of progressive Parkinson's disease.
Oiwa Y; Yoshimura R; Nakai K; Itakura T
Brain Res; 2002 Aug; 947(2):271-83. PubMed ID: 12176170
[TBL] [Abstract][Full Text] [Related]
11. Diagnostic value of combined assessment of olfaction and sustantia nigra hyperechogenicity for Parkinson's disease.
López Hernández N; García Escrivá A; Shalabi Benavent M
Neurologia; 2015 Oct; 30(8):496-501. PubMed ID: 24839905
[TBL] [Abstract][Full Text] [Related]
12. Selective expression of TLQP-21 and other VGF peptides in gastric neuroendocrine cells and modulation by feeding.
Brancia C; Cocco C; D'Amato F; Noli B; Sanna F; Possenti R; Argiolas A; Ferri GL
J Endocrinol; 2010 Dec; 207(3):329-41. PubMed ID: 20876237
[TBL] [Abstract][Full Text] [Related]
13. Regenerative effects of peptide nanofibers in an experimental model of Parkinson's disease.
Sever M; Turkyilmaz M; Sevinc C; Cakir A; Ocalan B; Cansev M; Guler MO; Tekinay AB
Acta Biomater; 2016 Dec; 46():79-90. PubMed ID: 27619838
[TBL] [Abstract][Full Text] [Related]
14. In vivo imaging of neuromelanin in Parkinson's disease using 18F-AV-1451 PET.
Hansen AK; Knudsen K; Lillethorup TP; Landau AM; Parbo P; Fedorova T; Audrain H; Bender D; Østergaard K; Brooks DJ; Borghammer P
Brain; 2016 Jul; 139(Pt 7):2039-49. PubMed ID: 27190023
[TBL] [Abstract][Full Text] [Related]
15. [Estrogen protects the dopaminergic neurons in substantia nigra against damage induced by 6-hydroxydopamine].
Meng JL; Ma YY; Luo HY; Kong SZ; He YW; Dong BC; Wu SH; He M
Sheng Li Xue Bao; 2008 Jun; 60(3):369-74. PubMed ID: 18560728
[TBL] [Abstract][Full Text] [Related]
16. Could VGF and/or its derived peptide act as biomarkers for the diagnosis of neurodegenerative diseases: A systematic review.
Alqarni S; Alsebai M
Front Endocrinol (Lausanne); 2022; 13():1032192. PubMed ID: 36619561
[TBL] [Abstract][Full Text] [Related]
17. Modulation of M1/M2 polarization by capsaicin contributes to the survival of dopaminergic neurons in the lipopolysaccharide-lesioned substantia nigra in vivo.
Bok E; Chung YC; Kim KS; Baik HH; Shin WH; Jin BK
Exp Mol Med; 2018 Jul; 50(7):1-14. PubMed ID: 29968707
[TBL] [Abstract][Full Text] [Related]
18. Electrophysiological characterization of substantia nigra dopaminergic neurons in partially lesioned rats: effects of subthalamotomy and levodopa treatment.
Bilbao G; Ruiz-Ortega JA; Miguens N; Ulibarri I; Linazasoro G; Gómez-Urquijo S; Garibi J; Ugedo L
Brain Res; 2006 Apr; 1084(1):175-84. PubMed ID: 16574080
[TBL] [Abstract][Full Text] [Related]
19. Olfactory mucosa is a potential source for autologous stem cell therapy for Parkinson's disease.
Murrell W; Wetzig A; Donnellan M; Féron F; Burne T; Meedeniya A; Kesby J; Bianco J; Perry C; Silburn P; Mackay-Sim A
Stem Cells; 2008 Aug; 26(8):2183-92. PubMed ID: 18535154
[TBL] [Abstract][Full Text] [Related]
20. Post-lesion administration of 7-NI attenuated motor and non-motor deficits in 6-OHDA induced bilaterally lesioned female rat model of Parkinson's disease.
Kumari R; Kumar JB; Luthra PM
Neurosci Lett; 2015 Mar; 589():191-5. PubMed ID: 25528406
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
